{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-21-003237","form_type":"8-K","ticker":"CMMB","cik":"0001534248","company_name":"Chemomab Therapeutics Ltd.","filed_at":"2021-10-25T23:59:59+00:00","discovered_at":"2026-05-14T18:04:12.943180+00:00","generated_at":"2026-06-28T18:26:47.290222+00:00","sec_items":["7.01","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"low","headline":"Chemomab Therapeutics files updated corporate presentation for October 2021","bullets":["Filed an updated corporate presentation covering its fibrotic disease pipeline.","Presentation date is October 2021; no specific financial or clinical data disclosed in the filing.","Presentation is furnished under Item 7.01 Regulation FD, not incorporated by reference.","No material changes to previously disclosed information are evident from the filing."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-21-003237","json":"https://secwatch.observer/filing/0001178913-21-003237.json","markdown":"https://secwatch.observer/filing/0001178913-21-003237.md","text":"https://secwatch.observer/filing/0001178913-21-003237.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534248/000117891321003237/0001178913-21-003237-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534248/000117891321003237/form8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T18:26:47.290222+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}